{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "P",
          "position": "30"
        },
        "variant_string_id": "SNCA A30P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Three familial variants of the presynaptic protein a-synuclein (aS), A30P, E46K, and A53T, correlate with rare inherited Parkinson's disease (PD), while wild-type aS is implicated in sporadic PD. The classic manifestation of both familiar and sporadic PD is the formation of fibrillar structures of as which accumulate as the main component in intraneuronal Lewy bodies.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as related to the formation of fibrillar structures of a-synuclein, which accumulate in Lewy bodies and are associated with Parkinson's disease. The variants are hypothesized to affect the partitioning of aS between disordered cytosolic and membrane-bound states, likely mediating its proposed role in regulation of reserve pools of synaptic vesicles.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Here, we report the phospholipid binding properties of the disease variants, viewed by solution NMR in a residue-specific manner.",
          "judgment": "Yes",
          "reasoning": "The phospholipid binding assay, as assessed by NMR, is applicable to the disease mechanism because the partitioning of aS between disordered cytosolic and membrane-bound states is thought to be related to its role in regulating synaptic vesicles and fibril formation.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Human wild-type aS with 15N and 2H isotopic enrichment was expressed and purified by anion-exchange chromatography as previously described (39). A30P, E46K, and A53T aS were expressed from recombinant plasmids produced by mutagenesis of the wild-type sequence using Quikchange mutagenesis reagents and standard PCR techniques.",
          "judgment": "Yes",
          "reasoning": "The study includes a wild-type control. The study also uses A30P aS made by mutagenesis. The methods section states that HSQC spectra were recorded, suggesting multiple replicates were performed. While not explicitly stated, it can be inferred that basic controls and replicates were included",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "Not applicable",
          "judgment": "No",
          "reasoning": "The paper does not explicitly state the use of known pathogenic or benign variants as controls. Nor does it mention variants tested that reach P/LP or B/LB criteria *without* relying on PS3/BS3 evidence themselves.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "A segment containing residues 11-23 exhibits progressively increasing resonance intensity, corresponding to an increasing fraction of the disordered population, and the attenuation shows a flat profile at ~75% intensity relative to the lipid-free state beginning from around residue 25, a point just preceding the mutation site.",
          "judgment": "No",
          "reasoning": "The paper provides experimental data on the phospholipid binding properties of A30P, but does not perform statistical analyses to estimate an OddsPath value.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "Not applicable",
          "judgment": "Yes",
          "reasoning": "Because the paper did not calculate an OddsPath, this step is relevant. The extracted paper includes data for the A30P variant and the wild-type control. Therefore, the total number of pathogenic/benign variants is less than 11.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The A30P variant exhibits altered phospholipid binding, specifically an increased fraction of the disordered population, suggesting it promotes aggregation under lipid-limiting conditions. This evidence is PS3_supporting because variant controls were not used and no oddsPath score was calculated. The functional assay does recapitulate the disease mechanism."
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "E",
          "alt": "K",
          "position": "46"
        },
        "variant_string_id": "SNCA E46K"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Three familial variants of the presynaptic protein a-synuclein (aS), A30P, E46K, and A53T, correlate with rare inherited Parkinson's disease (PD), while wild-type aS is implicated in sporadic PD. The classic manifestation of both familiar and sporadic PD is the formation of fibrillar structures of as which accumulate as the main component in intraneuronal Lewy bodies.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as related to the formation of fibrillar structures of a-synuclein, which accumulate in Lewy bodies and are associated with Parkinson's disease. The variants are hypothesized to affect the partitioning of aS between disordered cytosolic and membrane-bound states, likely mediating its proposed role in regulation of reserve pools of synaptic vesicles.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Here, we report the phospholipid binding properties of the disease variants, viewed by solution NMR in a residue-specific manner.",
          "judgment": "Yes",
          "reasoning": "The phospholipid binding assay, as assessed by NMR, is applicable to the disease mechanism because the partitioning of aS between disordered cytosolic and membrane-bound states is thought to be related to its role in regulating synaptic vesicles and fibril formation.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Human wild-type aS with 15N and 2H isotopic enrichment was expressed and purified by anion-exchange chromatography as previously described (39). A30P, E46K, and A53T aS were expressed from recombinant plasmids produced by mutagenesis of the wild-type sequence using Quikchange mutagenesis reagents and standard PCR techniques.",
          "judgment": "Yes",
          "reasoning": "The study includes a wild-type control. The study also uses E46K aS made by mutagenesis. The methods section states that HSQC spectra were recorded, suggesting multiple replicates were performed. While not explicitly stated, it can be inferred that basic controls and replicates were included",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "Not applicable",
          "judgment": "No",
          "reasoning": "The paper does not explicitly state the use of known pathogenic or benign variants as controls. Nor does it mention variants tested that reach P/LP or B/LB criteria *without* relying on PS3/BS3 evidence themselves.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The E46K aS variant displays an overall higher level of lipid partitioning of SL1, SL2, and all intermediate modes, relative to that of the wild type.",
          "judgment": "No",
          "reasoning": "The paper provides experimental data on the phospholipid binding properties of E46K, but does not perform statistical analyses to estimate an OddsPath value.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "Not applicable",
          "judgment": "Yes",
          "reasoning": "Because the paper did not calculate an OddsPath, this step is relevant. The extracted paper includes data for the E46K variant and the wild-type control. Therefore, the total number of pathogenic/benign variants is less than 11.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The E46K variant exhibits a higher level of lipid partitioning, suggesting it promotes aggregation under lipid-limiting conditions. This evidence is PS3_supporting because variant controls were not used and no oddsPath score was calculated. The functional assay does recapitulate the disease mechanism."
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "T",
          "position": "53"
        },
        "variant_string_id": "SNCA A53T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Three familial variants of the presynaptic protein a-synuclein (aS), A30P, E46K, and A53T, correlate with rare inherited Parkinson's disease (PD), while wild-type aS is implicated in sporadic PD. The classic manifestation of both familiar and sporadic PD is the formation of fibrillar structures of as which accumulate as the main component in intraneuronal Lewy bodies.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as related to the formation of fibrillar structures of a-synuclein, which accumulate in Lewy bodies and are associated with Parkinson's disease. The variants are hypothesized to affect the partitioning of aS between disordered cytosolic and membrane-bound states, likely mediating its proposed role in regulation of reserve pools of synaptic vesicles.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Here, we report the phospholipid binding properties of the disease variants, viewed by solution NMR in a residue-specific manner.",
          "judgment": "Yes",
          "reasoning": "The phospholipid binding assay, as assessed by NMR, is applicable to the disease mechanism because the partitioning of aS between disordered cytosolic and membrane-bound states is thought to be related to its role in regulating synaptic vesicles and fibril formation.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Human wild-type aS with 15N and 2H isotopic enrichment was expressed and purified by anion-exchange chromatography as previously described (39). A30P, E46K, and A53T aS were expressed from recombinant plasmids produced by mutagenesis of the wild-type sequence using Quikchange mutagenesis reagents and standard PCR techniques.",
          "judgment": "Yes",
          "reasoning": "The study includes a wild-type control. The study also uses A53T aS made by mutagenesis. The methods section states that HSQC spectra were recorded, suggesting multiple replicates were performed. While not explicitly stated, it can be inferred that basic controls and replicates were included",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "Not applicable",
          "judgment": "No",
          "reasoning": "The paper does not explicitly state the use of known pathogenic or benign variants as controls. Nor does it mention variants tested that reach P/LP or B/LB criteria *without* relying on PS3/BS3 evidence themselves.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "Among the three disease variants, the A53T mutation has the most subtle effect upon lipid binding... correlating to a modest elevation of the SL1 binding mode...",
          "judgment": "No",
          "reasoning": "The paper provides experimental data on the phospholipid binding properties of A53T, but does not perform statistical analyses to estimate an OddsPath value.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "Not applicable",
          "judgment": "Yes",
          "reasoning": "Because the paper did not calculate an OddsPath, this step is relevant. The extracted paper includes data for the A53T variant and the wild-type control. Therefore, the total number of pathogenic/benign variants is less than 11.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The A53T variant exhibits modest changes in phospholipid binding, specifically an elevation of the SL1 binding mode, suggesting it may promote aggregation under lipid-limiting conditions. This evidence is PS3_supporting because variant controls were not used and no oddsPath score was calculated. The functional assay does recapitulate the disease mechanism."
      }
  ]
}
